Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ranibizumab (Lucentis®) for restricted use within NHS Scotland for the treatment of adults with macular oedema secondary to central retinal vein occlusion (CRVO).
The Drug Advice discusses the evidence considered by the SMC (please see the link below for details). This notes that ranibizumab treatment was associated with significant improvements in visual acuity in one study of patients with branch retinal vein occlusion (BRVO) and in one study of patients with central (Read more...)